Gastrointestinal Stromal Tumors
Conditions
Keywords
GIST
Brief summary
This is a retrospective analysis and description of the preferred diagnostic and treatment methods employed on GIST on the Region of Coquimbo from 2003 to 2008.
Interventions
OTHERObservation
Not applied
Sponsors
Cirujanos la Serena
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All operated patients with GIST * Positive immunohistochemistry
Exclusion criteria
* Patients with GIST not operated * Patients with GIST operated on but without immunohistochemistry
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients Who Survived | 5 years | The outcomes were measured through follow-up visits of the patients to the out-patient clinic of our institution at 15 days, 1 month, 3 months, 6 months, 1 year, and after that, every year after the surgical treatment. |
Countries
Chile
Participant flow
Recruitment details
Hospital patients operated on for Gastrointestinal stromal tumor (GIST)
Pre-assignment details
The intention was to include all consecutive patients with GIST who presented during the study period. All consecutive patients with GIST were included during the study period
Participants by arm
| Arm | Count |
|---|---|
| Gastrointestinal Stromal Tumor (GIST) GIST in all locations: Stomach, duodenum, jejunum, ileum, and rectum. All patients were submitted to surgery and in 2 cases are on Imatinib therapy. | 24 |
| Total | 24 |
Baseline characteristics
| Characteristic | Gastrointestinal Stromal Tumor (GIST) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 2 Participants |
| Age, Categorical Between 18 and 65 years | 22 Participants |
| Age Continuous | 49 years STANDARD_DEVIATION 15.4 |
| Region of Enrollment Chile | 24 participants |
| Sex: Female, Male Female | 12 Participants |
| Sex: Female, Male Male | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
Primary
Number of Patients Who Survived
The outcomes were measured through follow-up visits of the patients to the out-patient clinic of our institution at 15 days, 1 month, 3 months, 6 months, 1 year, and after that, every year after the surgical treatment.
Time frame: 5 years
Population: This is a consecutive sample of all patients operated on for GISTs in 3 hospitals during a period of 5 years. The period of 5 years was determined by the time that we count with inmunochemistry to confirm GISTs at our institutions, and that time would be the last 5 years. The Last Observation Carried Dorward (LOCF) was made in August 2008.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Gastrointestinal Stromal Tumor (GIST) | Number of Patients Who Survived | 5 Participants |